Home / Weight Loss

Visceral Fat and Cardiovascular Risk in Men

Written by James T.

Published February 21, 2026

Visceral fat — the metabolically active fat stored deep in the abdominal cavity — is an independent driver of cardiovascular disease risk in men, and emerging evidence links it directly to endothelial dysfunction, the same vascular mechanism behind erectile dysfunction.

What Is Visceral Fat — and Why Does It Differ From Other Body Fat?

Not all fat is equivalent. The body stores two broad categories of adipose (fat) tissue: subcutaneous adipose tissue (SAT), which sits just beneath the skin, and visceral adipose tissue (VAT), which wraps around the internal organs within the abdominal cavity. You cannot pinch VAT — it doesn't register the same way on a scale — but it is metabolically far more consequential than fat stored elsewhere.

VAT is densely packed with immune cells and functions almost like an endocrine organ. It releases a continuous stream of pro-inflammatory cytokines (signaling proteins that promote inflammation), free fatty acids, and hormones such as resistin and angiotensinogen, all of which circulate directly to the liver and heart via the portal venous system. The net effect is a chronic, low-grade inflammatory state that damages arterial walls over years — long before any symptom appears.

A waist circumference above 40 inches (102 cm) in men is the threshold most frequently used in clinical practice, though imaging studies confirm that waist circumference alone underestimates VAT in some body types. The more precise measure is visceral adipose tissue area assessed by CT or MRI, though these are reserved for research settings.

The Cardiovascular Toll — What the Evidence Shows

The relationship between belly fat, heart disease, and metabolic disease is not theoretical. It is one of the most consistently replicated findings in cardiovascular medicine.

A landmark analysis published in *The Lancet* pooling data from 900,000 adults found that abdominal obesity was associated with significantly elevated risk of cardiovascular mortality, independent of overall body weight. Men with high VAT burden show elevated triglycerides, suppressed HDL cholesterol (the protective form), elevated fasting glucose, and elevated blood pressure — a cluster now classified as metabolic syndrome.

The mechanism begins at the arterial wall. VAT-derived inflammatory signals degrade the endothelium — the single-cell lining of every blood vessel in the body. Once the endothelium is damaged, it produces less nitric oxide (NO), the molecule responsible for arterial dilation and healthy blood flow. This is the same pathway that governs penile erections.

This is not a coincidence worth footnoting — it is a clinically actionable signal. During American Heart Month, it bears stating plainly: erectile dysfunction (ED) in a man between 45 and 70 is, until proven otherwise, a cardiovascular symptom. Research published in the *American Journal of Men's Health* and corroborated by data from the Massachusetts Male Aging Study confirms that ED frequently precedes a first cardiovascular event by three to five years. If you are experiencing ED alongside a growing waistline, that combination warrants a cardiovascular conversation with a licensed provider — not just a prescription.

What the Weight-Loss Trials Demonstrate

Two classes of medication are now supported by robust phase III trial data for visceral fat reduction: GLP-1 receptor agonists (semaglutide) and GIP/GLP-1 dual receptor agonists (tirzepatide).

The STEP trials (Semaglutide Treatment Effect in People with Obesity), published in the *New England Journal of Medicine*, enrolled adults with obesity or overweight plus a weight-related comorbidity. STEP 1 demonstrated significant reductions in total body weight versus placebo. Substudy imaging confirmed preferential reduction in VAT relative to subcutaneous fat. Results may vary.

The SURMOUNT trials (tirzepatide) extended this evidence base. SURMOUNT-1, also published in the *New England Journal of Medicine*, demonstrated dose-dependent reductions in body weight among adults with obesity. Cardiometabolic markers — triglycerides, blood pressure, waist circumference, and fasting glucose — improved in parallel with weight reduction. Results may vary.

Importantly, the SELECT trial (semaglutide in cardiovascular outcomes), published in the *New England Journal of Medicine* in 2023, enrolled over 17,600 adults with pre-existing cardiovascular disease and overweight or obesity. It demonstrated a statistically significant reduction in major adverse cardiovascular events (MACE) in the semaglutide group versus placebo — the first time a GLP-1 agent showed direct cardiovascular benefit in a dedicated outcomes trial.

Who Is — and Is Not — a Candidate

Potential candidates for pharmacologic weight management include men with a BMI (body mass index) ≥ 30, or ≥ 27 with at least one weight-related condition such as hypertension, type 2 diabetes, dyslipidemia, or obstructive sleep apnea.

Contraindications and cautions include a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN2), active pancreatitis, severe gastroparesis, or pregnancy. Men on insulin or sulfonylureas require careful monitoring for hypoglycemia when starting a GLP-1–based agent. The prescribing provider determines candidacy after a full medical intake — this list is not exhaustive.

What to Expect on Treatment

GLP-1 and dual agonist therapies are titrated (gradually increased) over several weeks to months to minimize gastrointestinal side effects, which are the most common adverse effects reported: nausea, constipation, and, less frequently, vomiting. These typically diminish as the body adjusts to each dose. Injection-site reactions are mild in most patients.

Meaningful changes in waist circumference and metabolic markers are generally observed within 12 to 16 weeks, though the full treatment course extends to one year or longer. We do not yet know the optimal duration of therapy or the best strategy for maintaining results after discontinuation — this remains an active research question.

Contact your provider promptly if you experience severe abdominal pain, persistent vomiting, vision changes, rapid heart rate, or signs of an allergic reaction.

The Good Guy Rx Pathway

Good Guy Rx is a technology platform connecting men to independent licensed physicians and independent state-licensed pharmacies. If your waist circumference, metabolic markers, or cardiovascular history suggest that VAT is a clinical concern, the prescribing provider determines whether a GLP-1 or dual agonist medication — including tirzepatide, prepared by state-licensed compounding pharmacies in accordance with FDA regulations — is appropriate after a complete medical intake. You can begin that intake now through the weight-loss assessment.

Sources

• Prospective Studies Collaboration — Whitlock et al., Body-mass index and cause-specific mortality — *The Lancet*, 200960318-4/fulltext)
• Wilding JPH et al. — Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1) — *New England Journal of Medicine*, 2021
• Jastreboff AM et al. — Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1) — *New England Journal of Medicine*, 2022
• Lincoff AM et al. — Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT) — *New England Journal of Medicine*, 2023
• Feldman HA et al. — Impotence and Its Medical and Psychosocial Correlates: Results of the Massachusetts Male Aging Study — *Journal of Urology*, 1994
• Janiszewski PM, Ross R — The Effect of Weight Loss Among Obese Men — *American Journal of Men's Health*, 2007
• American Heart Association — Metabolic Syndrome
• National Institutes of Health — Assessing Your Weight and Health Risk

This article is educational. A licensed provider determines whether you are a candidate after a medical intake.

Ready to start your journey?

Complete your free online visit and see if GLP-1 treatment is right for you.

Get Started

Related Articles

Microdose GLP-1: Managing Side Effects at Low Doses

James T. · Jun 27, 2026

Semaglutide ODT vs Injection: The Needle-Free Option

Marcus W. · Jun 26, 2026